Search

Search Constraints

You searched for: Author/Creator Uchibori, Ken

Search Results

1. A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114). Issue 9 (23rd March 2022)

2. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. (June 2020)

3. Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. (2020)

4. Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. Issue 10 (19th August 2019)

5. Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib. Issue 6 (7th May 2021)

6. Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2. Issue 6 (2nd February 2021)

7. Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. (July 2019)

8. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms. Issue 3 (8th February 2020)

9. Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice. Issue 4 (21st December 2020)

10. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. (March 2018)